Cancer Management and Research

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Self Screening for Cancer: Promises and Pitfalls" in Cancer Management and Research.

Cancer is a leading cause of death worldwide, and early detection can significantly improve prognosis. However, many individuals are not screened or are inadequately screened for cancer. Self-screening for cancer has the potential to lead to earlier detection, which in turn enables earlier treatment and better survival rates. It has also been touted as a way to reduce disparities in cancer outcomes, as self-screening kits could be made available to individuals without access to high-quality in-office screening. 

Self-collection methods have been implemented in several countries, and at-home collection kits for colorectal cancer screening and HPV testing have recently been approved in the United States. 

However, challenges remain for implementing self-screening and ensuring that this method of testing is accurate and accessible. 

We invite submissions on a range of subtopics related to self-screening for cancer, including but not limited to:

• Technological advancements in self-screening tools
• Accuracy and reliability of self-screening methods
• Regulation of self-screening tools
• Educational strategies for promoting accurate and effective self-screening
• Self-screening and overcoming disparities in cancer care
• Best practices for physicians (eg. de-escalate screening to primary HPV testing)
• Health systems implementation for successful screening

The deadline for submitting manuscripts is 31 July 2025. Please review the journal’s Aims and Scope of the journal and author submission instructions prior to submitting a manuscript. 

Please submit your manuscript on our website, quoting the promo code BJOFF for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.

Guest Advisor

Diane M. Harper, University of Michigan School of Medicine

Diane M. Harper is an internationally recognized family physician and clinical research expert in HPV-associated diseases, their prevention, early detection, and treatment for the prevention of cancer. She has been a consultant for the World Health Organization (WHO) and the Pan American Health Organization (PAHO) to advise on global guidelines and to set up screening and prevention operations in low and middle-income countries to prevent cervical cancer. She also has received the Distinguished Scientist Award from the European Research Organization on Genital Infection and Neoplasia for her scientific work as well as the Femmes de l'Année Prix Monte Carlo, which honors influential changemakers working to better women's lives around the world. As a physician-researcher, Dr. Harper has a strong interest in public health, epidemiology, and health behaviors, all fields in which she has published over her 30-year career. She has over 300 publications and tens of thousands of citations, has contributed to multiple textbooks, and has shaped global guidelines and policies related to cervical cancer screening and prevention efforts in the U.S., Europe, and for the WHO Elimination of Cervical Cancer Initiative.

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Immune Effector Cells for Cancer Therapy – CAR-T and beyond" in Cancer Management and Research.

Cellular therapies for both malignant and non-malignant disease have substantially grown in the past decade. Genetically engineered immune effector cells (IEC) have provided hope for patients with primary refractory malignancies and have received multiple regulatory approvals in B-cell lymphomas, acute lymphoblastic leukemia, and myelomas. Now the investigational portfolio of such promising treatment has grown substantially to include other cellular types (natural killer cells, and tumor infiltrating lymphocytes) and other malignancies including solid tumors. 

IEC were shown to be able to overcome resistance of malignant cells to treatment and have shown durable remissions in otherwise advanced malignancies with poor outcomes. The explosion of novel technologies beyond chimeric antigen receptor T-cells (CAR-T) to include T-cell receptor (TCR) engineered cells as well as other non-T cell therapy platforms like natural killer cells and tumor infiltrating lymphocytes expanded the application of such curative therapies beyond B-cell lymphomas and leukemias to other disease indications. 

This Article Collection welcomes submissions on topics including but not limited to:

• Optimization of already-approved IEC to improve outcomes and minimize toxicities
• Novel investigational cell therapy platforms and technologies in development
• Combination treatment with other agents like checkpoint inhibitors
• Expanding applications of IEC in solid tumors
• Strategies to modulate immunosuppressive tumor microenvironment,
• Expanding access to IEC through on site manufacturing,
• Methods to foster national and international collaborations to develop therapies for rare diseases
• Developing robust quality and regulatory infrastructures to ensure the safety of such promising therapies

The deadline for submitting manuscripts is 30 October 2025. Please review the journal’s Aims and Scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code VBJGE for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection. Please contact commissioning editor Cassie Houtz at [email protected] with any inquiries.

Guest Advisor

Basem M. William, MD, MRCP(UK), FACP

[email protected]

Professor Basem William is an internationally recognized expert in lymphoma, blood and marrow transplant, cellular therapy, and drug development. He is the inaugural Clinical Director of OhioHealth Blood and Marrow Transplant Program, Medical Director of Immune Effector Cell Program and Cell Therapy Laboratory, and John P. McConnell Endowed Chair for Cancer Research.

View all papers in this article collection

Cancer Management and Research is pleased to announce an upcoming Article Collection dedicated to the transformative role of CAR-T therapy in the management of cancer.

Since the 2017 US FDA approval of the use of anti-CD19 CAR-T cell therapy for use against B-cell malignancies, CAR-T therapy has demonstrated significant clinical benefits in treating hematologic malignancies, showing clinical efficacy and durability even in patients who have been refractory to other treatments. Research is underway to develop and evaluate CAR-based therapies for application in solid tumors. 

Despite the remarkable impact of CAR-T therapies, challenges remain, including antigen escape, limited persistence, and overcoming the immunosuppressive microenvironment. Further, life-threatening toxicities, the high costs of manufacturing, and the need for a well-trained workforce currently limit the widespread use of CAR-T for cancer treatment.

Given the impact and continued importance of CAR-T cell therapies in cancer treatment, Cancer Management & Research welcomes submissions of original research articles, reviews, and perspectives on CAR-T, including basic science, translational research, clinical efficacy, and real-world implementation. 

This Article Collection is part of a wider Game Changer Series focused on breakthrough therapies across medicine. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor & Francis and Dove Medical Press, increasing the discoverability and visibility of your research. 

The deadline for submitting manuscripts is 1 April 2026. Please review the journal’s Aims and Scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website. Submitting authors are eligible for a 20% discount on the Article Publishing Charge. To apply this discount, enter the code TFRFH when prompted during submission.

Please contact Commissioning Editor Cassie Houtz at [email protected] with any questions.

View all papers in this article collection